Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib.

× No keyword cloud information.

20 in total

Review 1. Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Authors: Lauren Caldemeyer; Michael Dugan; John Edwards; Luke Akard
Journal: Curr Hematol Malig Rep Date: 2016-04 Impact factor: 3.952

2. CML as Part of Dual Malignancies-A Retrospective Analysis: Possible Mechanisms and Review of Literature.

Authors: Kamal Kant Sahu; Yanamandra Uday; Amanjit Bal; Neelam Varma; Shano Naseem; Alka Khadwal; Gaurav Prakash; S Varma; Pankaj Malhotra
Journal: Indian J Hematol Blood Transfus Date: 2015-11-21 Impact factor: 0.900

3. Extranodal marginal zone B-cell lymphoma arising in chronic myeloid leukaemia successfully treated with tyrosine kinase inhibitor: a case report.

Authors: G Mihaylov; V Varbanova; V Stoeva; T Dikov
Journal: Hippokratia Date: 2016 Jul-Sep Impact factor: 0.471

4. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.

Authors: Dushyant Verma; Hagop Kantarjian; Sara S Strom; Mary Beth Rios; Elias Jabbour; Alfonso Quintas-Cardama; Srdan Verstovsek; Farhad Ravandi; Susan O'Brien; Jorge Cortes
Journal: Blood Date: 2011-08-16 Impact factor: 22.113

5. High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.

Authors: Josef Martz; Sarika Jain; Linda T Vahdat; Lihui Qin; Juan Miguel Mosquera; Cristina R Antonescu; Elizabeta C Popa
Journal: J Clin Oncol Date: 2013-02-25 Impact factor: 44.544

10. Metachronous Primary Adenocarcinoma of Lung During Adjuvant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach: A Case Report.

Authors: Meng-Jie Jiang; Shan-Shan Weng; Ying Cao; Xiao-Fen Li; Liu-Hong Wang; Jing-Hong Xu; Ying Yuan
Journal: Medicine (Baltimore) Date: 2015-09 Impact factor: 1.817

Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib.

Review 1. Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

2. CML as Part of Dual Malignancies-A Retrospective Analysis: Possible Mechanisms and Review of Literature.

3. Extranodal marginal zone B-cell lymphoma arising in chronic myeloid leukaemia successfully treated with tyrosine kinase inhibitor: a case report.

4. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.

5. High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.

6. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.

7. A rare case of chronic myelogenous leukemia and plasma cell myeloma in the same patient.

8. Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

9. The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2).

10. Metachronous Primary Adenocarcinoma of Lung During Adjuvant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach: A Case Report.